Clinical Trials Browser

Phase 1/2 × Human Papillomavirus Recombinant Vaccine nonavalent × Gynecologic × Clear all

NCT05496231 2025-02-03

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Phase 1/2 Completed

1,080 enrolled 28 charts

Uterine Cervical Dysplasia, Infections